VERU
Veru Inc.2.4400
+0.0500+2.09%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
39.16MP/E (TTM)
0.41Basic EPS (TTM)
6.00Dividend Yield
0%Recent Filings
8-K
Regains Nasdaq listing compliance
10-Q
Q3 FY2025 results
Veru Inc. narrowed its Q3 FY2025 operating loss from continuing operations to $7.5M, a 28% improvement y/y from $10.5M, driven by 38% lower R&D spend at $3.0M amid the ongoing Phase 2b enobosarm trial for obesity-related muscle preservation, while SG&A held steady at $5.0M. Net loss eased to $7.3M from continuing ops ($0.50/share), with the full-year nine-month figure at $17.0M ($1.16/share), bolstered by an $8.6M gain on extinguishing the SWK royalty debt tied to the December 2024 FC2 sale. Cash dipped to $15.0M from $24.9M y/e, after netting $16.3M from the FC2 divestiture and $4.2M debt payoff, leaving ample runway for near-term trials but flagging going-concern doubts without fresh funding. The FC2 exit sharpened focus on biopharma, yet litigation shadows from the deal and shareholder suits loom large.
8-K
Enobosarm preserves muscle in weight loss
Veru Inc. reported positive Phase 2b results for enobosarm, showing 100% lean mass preservation and 46% less weight regain versus placebo when added to semaglutide, alongside greater fat loss and fewer GI side effects. The company selected a novel modified-release oral formulation after a pharmacokinetic study, bolstering IP through 2046. Q3 net loss narrowed to $7.3 million from $11.0 million, with cash at $15.0 million. FDA feedback on the regulatory path awaits.
8-K
Veru enacts 1-for-10 split
Veru Inc. executed a 1-for-10 reverse stock split on August 8, 2025, effective at 11:59 pm CT, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. Trading on a split-adjusted basis resumes August 11 under the same symbol VERU but with new CUSIP 92536C202; no fractional shares issued, cash paid instead. Equity plans adjusted proportionally. This bolsters listing status amid clinical-stage biopharma pressures.
8-K
Shareholders approve reverse split
Veru Inc. shareholders approved a reverse stock split at a special meeting on July 25, 2025, authorizing the board to select a ratio from 1-for-2 to 1-for-20. With 98.9 million votes in favor against 7.1 million opposed, the move aims to boost share price and meet Nasdaq requirements. The adjournment proposal also passed overwhelmingly. Board will decide the exact ratio soon.
ABVC
ABVC Biopharma, Inc.
2.06-0.01
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
ENVB
Enveric Biosciences, Inc.
5.24-0.12
EVFM
Evofem Biosciences, Inc.
0.01-0.00
TELO
Telomir Pharmaceuticals, Inc.
1.40-0.02
VCEL
Vericel Corporation
35.50-0.99
VIR
Vir Biotechnology, Inc.
6.48-0.24
VNDA
Vanda Pharmaceuticals Inc.
6.65+0.02
VRNA
Verona Pharma plc
106.91+0.00
VSTM
Verastem, Inc.
8.64-0.63